Research Summary
This human clinical study investigated plasma thymosin beta-4 (Tβ4) levels in chronic ischemic heart failure patients who received intracardiac cell therapy and found that increased plasma Tβ4 was associated with symptomatic improvement in these patients. The research suggests a potential biomarker relationship between Tβ4 elevation and clinical outcomes following cell-based cardiac intervention. This is human clinical-level evidence examining the mechanistic relationship between a circulating peptide and therapeutic response in heart failure patients.